Trial reportBMC oral health2026
Synovial fluid level of myeloperoxidase enzyme following ultrasound-guided regenerative injections in patients with irreducible temporomandibular disc displacement: a double-blinded parallel randomized clinical trial.
Trial report in BMC oral health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04557878 (Role of Liquid Phase Concentrated Growth Factors vs. Hypertonic Dextrose Prolotherapy for Management of Patients With Disc Displacement Without Reduction), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Role of Liquid Phase Concentrated Growth Factors vs. Hypertonic Dextrose Prolotherapy for Management of Patients With Disc Displacement Without Reduction (A Randomized Clinical Trial)
Who cites it
2 citing papers in PubMed.
- Outcome Analysis of Leukocyte-Rich Platelet-Rich Plasma, Leukocyte-Poor Platelet-Rich Plasma, and Injectable Platelet-Rich Fibrin in the Management of Chronic Plantar Fasciitis: A Prospective Comparative Study.Journal of orthopaedic case reports · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIrreducible temporomandibular disc displacement (DDwoR) is a subtype of internal derangement of temporomandibular joint (TMJ-ID). Recognizing the risks related to DDwoR with its pathogenesis, the treatment of this disorder becomes essential. Prolotherapy, also known as regenerative injection therapy, has been emerging as one of the most promising approaches to treat patients with TMJ-ID. The current prospective parallel randomized clinical trial (RCT) was done to assess the effect of hypertonic dextrose (HD) regenerative injection and that of concentrated growth factors (CGF) in conjunction with a stabilization occlusal appliance (SA) in the management of DDwoR.
methodsTwenty-four patients suffering from DDwoR were randomly assigned to 2 equal groups; Group I (HD + SA), Group II (CGF + SA). Assessments were done before treatment, 1 week, 4 weeks, and 24 weeks after the treatment using the Visual Analogue Scale of Pain (VAS) and assisted maximum mouth opening (MMO). Moreover, synovial fluid (SF) samples were obtained for the analysis of the Myeloperoxidase enzyme (MPO) levels, before and 6 months after treatment.
resultsA significant relief in pain was found in both groups at 1 month and lasted up to 6 months postoperatively (p < 0.001). Moreover, assisted MMO in both groups was significantly increased (p < 0.001). As for MPO levels in SF, by 6-months from the intra-articular injection, the enzyme levels were significantly reduced in both groups (p = 0.002). Although the MPO concentrations in the SF were significantly higher than that found after injection, there was a statistically insignificant difference between groups.
conclusionsWe concluded that injection of HD or CGF in the superior joint space could be a valuable treatment option for patients suffering from DDwoR. As both led to a positive impact on MMO, and the relief of joint pain with the decrease in levels of inflammatory biomarker inside the joint.
trial registrationThe current trial is a prospective assessor and analyst blinded RCT that has been registered at ClinicalTrials.gov with identification number: NCT04557878, 1/4/2020.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.